CYCLOOXYGENASES 1 AND 2

Annual Review of Pharmacology and Toxicology - Tập 38 Số 1 - Trang 97-120 - 1998
John R. Vane1, Y.S. Bakhle1, Regina M. Botting1
1The William Harvey Research Institute, St Bartholomew's and the Royal London School of Medicine and Dentistry, Queen Mary and Westfield College, Charterhouse Square, London EC1M 6BQ, United Kingdom

Tóm tắt

▪ Abstract  Cyclooxygenase (COX), first purified in 1976 and cloned in 1988, is the key enzyme in the synthesis of prostaglandins (PGs) from arachidonic acid. In 1991, several laboratories identified a product from a second gene with COX activity and called it COX-2. However, COX-2 was inducible, and the inducing stimuli included pro-inflammatory cytokines and growth factors, implying a role for COX-2 in both inflammation and control of cell growth. The two isoforms of COX are almost identical in structure but have important differences in substrate and inhibitor selectivity and in their intracellular locations. Protective PGs, which preserve the integrity of the stomach lining and maintain normal renal function in a compromised kidney, are synthesized by COX-1. In addition to the induction of COX-2 in inflammatory lesions, it is present constitutively in the brain and spinal cord, where it may be involved in nerve transmission, particularly that for pain and fever. PGs made by COX-2 are also important in ovulation and in the birth process. The discovery of COX-2 has made possible the design of drugs that reduce inflammation without removing the protective PGs in the stomach and kidney made by COX-1. These highly selective COX-2 inhibitors may not only be anti-inflammatory but may also be active in colon cancer and Alzheimer's disease.

Từ khóa


Tài liệu tham khảo

10.1073/pnas.85.5.1412

Merlie JP, 1988, J. Biol. Chem., 263, 3550, 10.1016/S0021-9258(18)68959-8

10.1016/0014-5793(88)80847-0

10.1016/0929-7855(95)00015-I

10.1016/0005-2760(95)00194-8

10.1155/S0962935196000452

10.2165/00003495-199753040-00003

Vane JR, 1971, Nature, 231, 232

10.1038/nsb1196-927

10.1038/384644a0

10.1038/367243a0

10.1016/0014-5793(94)80579-2

Lecomte M, 1994, J. Biol. Chem., 269, 13207, 10.1016/S0021-9258(17)36820-5

O'Neill GP, 1994, Mol. Pharmacol., 45, 245

10.1002/(SICI)1098-1128(199603)16:2<181::AID-MED3>3.3.CO;2-Y

10.1074/jbc.272.14.9280

10.1074/jbc.271.26.15810

10.1074/jbc.271.32.19134

10.1074/jbc.270.49.29372

10.1074/jbc.271.33.20175

10.1006/abbi.1995.1100

10.1006/abbi.1995.0027

10.1006/abbi.1993.1168

10.1074/jbc.270.18.10902

Otto JC, 1994, J. Biol. Chem., 269, 19868, 10.1016/S0021-9258(17)32100-2

Onoe Y, 1996, J. Immunol., 156, 758, 10.4049/jimmunol.156.2.758

10.1053/gast.1996.v111.pm8690211

10.1172/JCI119296

Ristimäki A, 1997, Cancer Res., 57, 1276

10.1016/B978-0-12-198875-3.50009-8

10.1172/JCI117620

10.1042/bj3130617

10.1136/bmj.308.6921.81

10.1007/BF00053030

10.1016/S0140-6736(05)62229-5

10.1677/joe.0.1500497

10.1016/S0143-4004(96)90044-2

10.1210/jc.81.3.1283

10.1677/jme.0.0160107

10.1210/en.136.4.1610

10.1016/0090-6980(96)00005-6

10.1677/joe.0.1510125

10.1016/0092-8674(95)90126-4

10.1016/0092-8674(95)90125-6

10.1038/378406a0

Richards JS, 1995, Rec. Prog. Hormone Res., 50, 223

10.1016/0092-8674(95)90109-4

10.1177/019262339602400607

10.1016/0896-6273(93)90192-T

10.1002/cne.903550208

10.1016/0006-8993(95)01474-8

Jones SA, 1993, Am. J. Physiol., 264, R135, 10.1152/ajpcell.1993.264.3.C609

10.1016/0014-5793(96)00604-7

10.1016/0014-5793(93)80263-T

10.1073/pnas.90.19.9070

Blatteis CM, 1997, News Physiol. Sci., 12, 1

10.1016/0006-8993(96)00575-6

10.1002/(SICI)1096-9861(19970505)381:2<119::AID-CNE1>3.0.CO;2-6

Cao C, 1997, Am. J. Physiol., 272, R1712

10.1038/240200a0

10.1038/sj.bjp.0701148

10.1111/j.1476-5381.1991.tb12502.x

10.1111/j.1476-5381.1992.tb14503.x

10.1016/0006-8993(95)00133-B

10.1007/BF02311085

10.1126/science.1381521

10.1016/S0006-8993(96)00817-7

Gardiner NJ, 1997, Br. J. Pharmacol., 120, 71P

10.1038/sj.bjp.0701548

10.1016/0929-7855(95)00029-P

10.1016/0092-8674(95)90194-9

10.1016/0092-8674(95)90193-0

10.1016/0092-8674(95)90200-7

10.1016/0014-5793(95)00703-C

10.1016/S0092-8674(00)81983-2

10.1016/0092-8674(95)90127-2

10.1073/pnas.92.17.7961

10.2165/00003495-199346010-00001

Furst DE. 1997. Meloxicam: selective COX-2 inhibition in clinical practice. InSelective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential, ed. JR Vane, JH Botting. London: Kluwer/William Harvey Press. In press

10.1021/jm960803q

10.1038/sj.bjp.0701076

Lanza F, 1997, Gastroenterology, 112, A194

Lanza FL, 1997, Gastroenterology, 112, A194

Hubbard RC, 1996, J. Invest. Med., 44, 293A

Ehrich E, 1996, Arthritis Rheum., 39, S81, 10.1002/art.1780390111

Chan C-C, 1995, J. Pharmacol. Exp. Ther., 274, 1531

10.1053/gast.1997.v112.agast970645

10.1053/gast.1997.v112.pm9024292

10.1016/S0092-8674(00)81333-1

10.1056/NEJM199509073331001

Thun MJ, 1996, Cancer Res., 53, 1322

10.7326/0003-4819-121-4-199408150-00001

10.1056/NEJM199305063281805

10.1016/0016-5085(94)90246-1

10.1016/S0092-8674(00)81988-1

Samaha HS, 1997, Cancer Res., 57, 1301

10.1136/gut.40.3.344

Ford-Hutchinson AW. 1997. New highly selective COX-2 inhibitors. InSelective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential, ed. JR Vane, JH Botting. London: Kluwer/William Harvey Press. In press

Parrett ML, 1997, Int. J. Oncol., 10, 503

10.1016/0952-3278(95)90051-9

Thompson HJ, 1997, Cancer Res., 57, 267

10.1517/13543784.5.4.449

10.1146/annurev.med.47.1.401

10.1016/0165-0173(95)00011-9

10.1212/WNL.48.3.626

Hampel H, 1995, Drug News Perspect., 8, 599

10.1111/j.1432-1033.1997.00726.x

10.1016/S0197-4580(96)00110-8

10.1212/WNL.43.8.1609

10.1073/pnas.90.24.11693

Patrignani P, 1997, J. Physiol. Pharmacol.

Meade EA, 1993, J. Biol. Chem., 268, 6610, 10.1016/S0021-9258(18)53294-4

10.1016/0006-2952(95)02111-6

10.1016/0006-2952(94)90205-4

10.1016/0090-6980(94)90074-4

Laneuville O, 1994, J. Pharmacol. Exp. Ther., 271, 927

10.1042/bj3050479

10.1007/BF02735467

Patrignani P, 1994, J. Pharmacol. Exp. Ther., 271, 1705

10.1007/BF02259611

10.1007/BF02265118

Warner TD, 1995, Inflamm. Res., 44, S274, 10.1007/BF01778335

10.1007/978-94-011-5386-7_1

10.1016/0167-4838(94)90148-1

10.1016/S0006-2952(96)00599-0

Carabaza A, 1996, Prostaglandins Leukot. Essent. Fatty Acids, 55, 93

10.1016/0014-2999(95)00302-2

Thông tin
Thông tin xuất bản

Annual Review of Pharmacology and Toxicology

Tập 38 Số 1

97-120

Thông tin tác giả